
    
      BPI-3016 is a novel analogue of glucagon-like peptide-1 (GLP-1) that developed for the
      treatment of type 2 diabetes mellitus. This is a randomized, double-blind,
      placebo-controlled, dose finding study evaluating the safety, pharmacokinetics and
      pharmacodynamics of subcutaneously injected BPI-3016 in Chinese healthy subjects.
    
  